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Abstract:  Problem  statement:  Leukemia  is  a  cancer  which  linked  intimately  with  the  immune 
system. It is a group of heterogenous neoplastic disorder of white blood cells characterized by the 
uncontrolled proliferation and block in differentiation of hematopoeitic cells. Generally, leukemia can 
be classified into myeloid or lymphoid referring to the type of abnormal cell found most in the blood. 
Approach: Many drug discovery researches have utilized the leukemic cell lines to screen for their 
potential as chemotherapy agents for leukemia. Results: The understanding on the types of leukemia 
and current choice of chemotherapy drugs can help to select the best target cell lines to study and the 
most suitable chemotherapy  drug as positive control. Conclusion/Recommendations: This review 
cover  types  of  leukemia,  current  option  of  chemotherapy  drugs  and  some  potential  cytotoxic  and 
immunomodulatory natural products targeting leukemic cancer cell line.  
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INTRODUCTION 
 
  Cancer  is  a  heterogeneous  group  of  diseases, 
characterized by uncontrolled growth of cell population 
(Gomathi and Thangaraj, 2010). Continuous division of 
these  cells  results  in  the  formation  and  growth  of 
tumors.  Tumors  are  classified  with  reference  to  a 
number  of  criteria  including  their  behavior,  their 
appearances  and  their  origins  (Evans,  1991).  Cancer 
cells  escape  from  many  of  the  normal  homeostatic 
mechanism that control proliferation (Goodman, 2008).  
  Clinical  experience  indicates  that  there  are  two 
fundamental  types  of  tumors,  benign  and  malignant, 
which behave in different ways (Darnell et al., 1986). 
Benign tumors remain localized and do not spread to 
different part of body (Evans, 1991). Malignant tumors 
do not remain localized and encapsulated. They invade 
surrounding  tissues,  get  into  the  body’s  circulating 
system and set up areas of proliferation away from the 
site of their original appearance (Darnell et al., 1986). 
  Most  tumors  contain  alterations  in  both  tumor-
suppressor  genes  and  oncogenes,  suggesting  that  the 
lost of a tumor-suppressor genes function within a cell 
must be accompanied by the conversion or activation of 
proto-oncogenes  into  an  oncogene  before  the  cell 
becomes  fully  malignant  (Becker  et  al.,  2000).  Proto-
oncogenes  and  tumor-suppressor  genes  encode  many 
kinds  of  proteins  that  help  control  cell  growth  and 
proliferation. Mutations in these genes can contribute to 
the development of cancer (Lodish et al., 2000).  
  Cancerous  tumor  is  the  disease  of  malignant 
tumors. Malignant tumors or cancer are aggregates of 
cells  caused  by  a  series  of  chromosomal  changes. 
Cancer cells often differ from their normal neighbors by 
a  host  of  specific  phenotypic  changes,  such  as  rapid 
division rate, invasion of new cellular territories, high 
metabolic  rate  and  altered  shape.  Transformation  of 
normal cells to malignant cells may triggered by several 
factors  including  chemical  exposure,  viruses  and 
radiations. It also can occur deliberately under cellular 
control  during  the  processes  such  as  meiosis  or 
hypermutation (Alves et al., 2011; Lodish et al., 2000). 
  Cancers  originate  within  a  single  cell.  Hence, 
cancers can be classified by the type of cell in which it 
originates and by the location of the cell as carcinomas, 
adenocarcinomas,  malignant  melanoma,  sarcomas, 
leukemias,  lymphomas  or  teratocarcinomas. 
Carcinomas  originate  in  epithelial  cells. 
Adenocarcinomas  originate  from  glandular  epithelial 
tissue.  Malignant  melanoma  arises  in  melanocytes,  a 
pigmented  epithelial  cell.  Sarcoma  begins  in  the 
connective tissue of bone or muscle. Leukemias start in Am. J. Immunol., 7 (4): 54-61, 2011 
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the  bone  marrow  stem  cells.  Lymphoma  is  a  cancer 
originating in lymphatic tissue. Teratocarcinomas begin 
within germ cells (Evans, 1991). 
 
Leukemia:  Leukemia  is  a  cancer  which  linked 
intimately with the immune system. It is a malignant 
hematopoietic disease characterized by an uncontrolled 
proliferation  and  block  in  differentiation  of 
hematopoietic cells (Lee et al., 2007). These malignant 
cells can spread to the lymph nodes, spleen, liver and 
other tissues. Leukemia is broadly classified as acute or 
chronic referring to the type of cell affected and by the 
rate of cell growth and of myeloid or lymphoid according 
to the type of cell that is multiplying abnormally. Acute 
leukemia signifying rapidly progressing disease  with a 
presence  of  immature,  blast  cells,  while  chronic 
leukemia, denotes slowly progressing disease with more 
mature  and  well-differentiated  cells.  Some  chronic 
leukemia  may  transform  into  an  acute  phase  as  “blast 
crisis” (Leonard, 1998).  
  The  leukemias  are  classified  in  accordance  with 
silent pathological features of the abnormal excessive 
hemopoietic cells (Mughal and Goldman, 2003). They 
are four major subtypes of leukemia and several rare 
forms.  The  acute  leukemias  are  divided  into  Acute 
Myeloid  Leukemia  (AML)  and  Acute  Lymphocytic 
Leukemia  (ALL).  The  chronic  leukemias  are  divided 
into  Chronic  Myeloid  Leukemia  (CML)  and  Chronic 
Lymphocytic  Leukemia  (CLL).  Other,  rare  types  of 
leukemia  include  hairy  cell  leukemia,  sezary  cell 
leukemia,  plasma  cell  leukemia,  prolymphocytic 
leukemia and the leukemia phase of lymphoma (Ball 
and  Kagan,  2007).  According  to  Lee  et  al.  (2007), 
leukemia might affect people of all ages. 
 
Type of leukemia: 
Acute  Myeloid  Leukemia  (AML):  Acute  myeloid 
leukemia or Acute Myelogenous Leukemia (AML) is 
characterized  by  the  malignant  transformation  of 
myeloid stem cells in the bone marrow, which are in 
capable  of  normal  differentiation  and  maturation 
(Mughal and Goldman, 2003). This type of leukemia is 
also  referred  to  as  Acute  Nonlymphocytic  Leukemia 
(ANLL)  because  nonlymphoid  cells  are  affected 
(Lowenberg  et  al.,  1999).  Since  the  normal 
hematopoiesis  is  organized  hierarchically,  the 
malignant  transformation  can  occur  at  several  levels. 
AML may arise in a stem cell capable of differentiating 
into  cells  of  erythroid,  granulocytic,  monocytic  and 
megakaryocytic lineages, or in a lineage-restricted stem 
cell  (Mughal  and  Goldman,  2003).  AML  is  most 
common  between  ages  63-65  years  among  adults 
(Lowenberg et al., 1999). 
Table 1: French-American-British  (FAB)  classification  of  Acute 
Myeloid Leukemia 
Designation  Description 
M0  Undifferentiated leukemia 
M1  Acute myeloblastic leukemia with immature cells 
M2  Acute myeloblastic leukemia with some mature cells 
M3  Acute promyelocytic leukemia 
M4  Acute myelomonocytic leukemia 
M5  Acute monocytic leukemia 
M6  Erythroleukemia (immature red and white blood cells) 
M7  Acute megakaryocytic leukemia (immature platelets 
  megakaryocytes) 
(Leonard, 1998) 
 
  Most  patients  with  AML  present  with  signs  and 
symptoms arising from bone marrow failure and organ 
infiltration  by  leukemic  cells.  Occasionally,  patients 
may present as a consequence of hyperleucostasis. The 
diagnosis  of  AML  is  made  when  more  than  30%  of 
blast cells (myeloblasts) are found in bone marrow or 
peripheral  blood  (Mughal  and  Goldman,  2003).  This 
results  in  anemia,  thrombocytopenia  and 
granulocytopenia  with  obvious  symptoms  such  as 
fatigue,  fever,  dizziness,  infection  and  bleeding.  This 
disease  has  a  very  rapid  onset.  Without  treatment,  a 
patient  only  rarely  survives  more  than  6-12  months 
(Mattiuzzi et al., 2003).  
  AML  is  classically  subdivided  into  subtypes  L0 
through  L7  based  on  the  various  degrees  of 
differentiation and the lineage of cell maturation using 
the  French-American-British  (FAB)  classification 
(Table  1).  M1,  M2  and  M3  leukemia  show 
predominantly  granulocytic  differentiation  and  differ 
from  one  another  in  the  extent  and  nature  of 
granulocytic  maturation.  M4  shows  both  granulocytic 
and  monocytic  differentiation  and  M5  shows 
predominantly  monocytic  differentiation.  They  are 
usually  monoblast  in  M5.  M6  shows  predominantly 
erythroblastic differentiation and M7 is associated with 
leukemic megakaryocytes (Bennett et al., 1985). 
 
Acute  Lymphocytic  Leukemia  (ALL):  Acute 
Lymphocytic  Leukemia  (ALL)  also  known  as  acute 
lymphoblastic leukemia is a cancer of lymphocytes. It 
is  characterized  by  abnormalities  of  lymphoid  cell 
precursors,  leading  to  excessive  accumulation  of 
leukemic lymphoblasts in the marrow and other organs, 
in  particular  the  spleen  and  liver  (Mughal  and 
Goldman, 2003). ALL is the most common cancer in 
children between the ages of 2 and 3 years (Gustafsson 
et  al.,  1998).  Approximately  85%  of  leukemia  in 
children derived from the acute types (Anino et al., 
2002;  Fitri  et  al.,  2011).  Since  it  affects  mainly 
children,  emotion  regulation  has  been  identified  as 
one  of  the  key  point  of  consideration  during 
undergoing chemotherapy (Fitri et al., 2011). It also 
affects adults, mainly those between 30 and 50 years 
of  ages,  accounting  for  20%  of  all  adult  acute Am. J. Immunol., 7 (4): 54-61, 2011 
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leukemia. The disease is biologically and clinically 
heterogeneous  and  the  immunophenotypic 
heterogeneity  of  ALL  gradually  emerged  with  age 
(Mughal and Goldman, 2003). 
  The presenting features of  ALL are result of the 
depressed  hematopoiesis  due  to  the  overgrowth  of 
leukemic  cells  in  the  bone  marrow.  Almost  80%  of 
patients with ALL have lymphadenopathy. The lymph 
nodes are usually painless and movable, the spleen and 
liver are also frequently enlarged, with up to 70-75% of 
patients  presenting  with  hepatomegaly  and/or 
splenomegaly. The most common initial symptoms of 
ALL  are  attributable  to  anemia,  neutropenia  and 
thrombocytopenia.  They  are  manifested  by  fatigue, 
weakness, fever, weight loss and bleeding (Henderson 
and Afshani, 1990). Rarely, patients may present with 
respiratory  difficulties  as  a  consequence  of  a 
mediastinal mass (Mughal and Goldman, 2003). 
  ALL is divided into subgroups L1-L3 categorized 
according  to  the  French-American-British  (FAB) 
Classification  based  on  the  appearance  of  the 
leukemia or blast cells (Table 2). In the subtype L1, 
the  lymphoblast  is  relatively  small  with  scanty 
cytoplasm  and  inconspicuous  nucleoli.  The 
lymphoblast is larger with more abundant cytoplasm 
in the subtype L2. In the subtype L3, the lymphoblast 
is mature and resembles the Burkitt’s-Like leukemia 
(Mughal and Goldman, 2003). 
 
Chronic Myeloid Leukemia (CML): Chronic Myeloid 
Leukemia  (CML)  is  also  known  as  chronic  myeloid, 
chronic  myelocytic  leukemia  or  chronic  granulocytic 
leukemia. CML is a clonal disease that results from an 
acquired genetic change in a pluripotential hemopoietic 
stem  cell  (Mughal  and  Goldman,  2003).  CML  is  a 
myeloproliferative disorder characterized by a biphasic 
or triphasic clinical course in which a benign chronic 
phase is followed by transformation into an accelerated 
and  blastic  phase  (Faderl  et  al.,  1999).  It  is 
characterized  by  the  uncontrolled  proliferation  of 
granulocytes and usually accompany with proliferation 
of  erythroid  cells  and  megakaryocytes.  This  disease 
occurs  mainly  in  adults  and  very  small  numbers  of 
children  develop  this  disease  (Mughal  and  Goldman, 
2001; Melo and Chuah, 2007).  
  Common  early  symptoms  of  CML  are  fatigue, 
tiring easily, weight loss and a sense of fullness in the 
upper abnormal from an enlarged spleen, which is the 
most common finding at diagnosis. The swollen spleen 
(splenomegaly)   may   fill    most   of    the    abdomen. 
Table 2: French-American-British  (FAB)  classification  of  acute 
lymphocytic leukemia 
Designation  Description 
L1  The lymphoblasts tend to be small, with little 
  cytoplasm and regularly shaped nuclei; they are 
  more mature in appearance than other subtypes 
L2  The lymphoblasts appear more immature, 
  varying in size and nuclear shape 
L3  The lymphoblasts tend to be large, with 
  abundant cytoplasm and similarly shaped nuclei. 
(Leonard, 1998) 
 
Headaches, sweating, fever and bone pain or tenderness 
also  may  occur.  About  90%  of  CML  patient  have  a 
genetic translocation between chromosom 9 and 22 in 
their  leukemic  cells  called  the  Philadelphia 
chromosome  (Ph
1)  causes  uncontrolled  reproduction 
and  proliferation  of  white  blood  cells  and  platelets 
(Leonard, 1998). 
  In later stages of the disease, however the leukemic 
cells lose the ability to mature and blast cells begin to 
build up in the bone marrow and blood. CML has three 
distinct phases, the chronic phase, the accelerated phase 
and the blast phase (or crisis). In the chronic phase (the 
most common at diagnosis), there are few blast cells 
and promyelocytes in the blood and bone marrow. This 
phase may last from several months to several years. 
More blast cells and fewer normal cells are found in the 
bone marrow and blood in the accelerated phase. In the 
blast phase, more than 30% of the cells in the blood or 
bone  marrow  are  blast  cells.  During  blast  phase, 
collections of blast cells may form tumors in the bones 
or lymph nodes (Leonard, 1998). 
  Transition  from  the  chronic  phase  to  the 
accelerated  and  later  the  blast  phase  may  occur 
gradually over a year or more, or it may occur abruptly. 
This  new  phase  is  referred  to  as  “blast  crisis”.  Blast 
crisis occur an average of 3-5 years after diagnosis and 
is very similar to aggressive acute leukemia but more 
difficult to treat (Leonard, 1998). 
 
Chronic  Lymphocytic  Leukemia  (CLL):  Chronic 
Lymphocytic Leukemia (CLL) is also known as chronic 
lymphatic  leukemia.  CLL  typically  consists  of  clonal 
expansion of mature, long-lived, functionally deficient 
B-lymphocytes  that  express  high  levels  of  the  anti-
apoptotic protein BCL-2 (Hanada et al., 1993). In 95% 
of  cases,  CLL  is  a  predominantly  malignant  clonal 
disorder of B lymphocytes. The remainder is secondary 
to a T-cell clone. The neoplastic cell is a hypoproliferative, 
immunologically incompetent small lymphocyte. There is 
primary involvement of the bone marrow and secondary 
release into the peripheral blood. The re-circulating 
lymphocytes   selectively  infiltrate the lymph nodes, 
the    spleen   and    he    liver    (Pepper et al., 1996). Am. J. Immunol., 7 (4): 54-61, 2011 
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Table 3: Rai staging system for chronic lymphocytic leukemia 
Stage  Description 
0  Absolute lymphocytosis 
1  Absolute lymphocytosis and lymphadenopathy 
2  Absolute lymphocytosis and splenomegaly or hepatomegaly 
3  Absolute lymphocytosis and anemia (hemoglobin < 11g dL
-1) 
4  Absolute lymphocytosis and thrombocytopenia 
  (platlets < 100 000  L
-1)  
(Mughal and Goldman, 2003) 
 
Table 4: Binet Staging System for Chronic lymphocytic leukemia 
Stage  Description 
A  Two or fewer lymphoid-bearing areas.  
B  Three or more lymphoid-bearing areas. 
C  Presence of anemia (hemoglobin < 10g dL
-1) and/or 
  thrombocytopenia (platlets < 100 000  L
-1) 
(Mughal and Goldman, 2003) 
 
It  is  the  most  common  type  of  leukemia  in  the 
western word, accounting for more than 30% of all 
leukemias, affects people over age of 40 years, but it 
almost  never  affects  children  (Pepper  et  al.,  1996; 
Mughal and Goldman, 2001). 
  CLL is primary a disease of the elderly, with the 
media age of onset being 65 year. Patients with CLL 
may have general feeling of ill health, fatigue, lack of 
energy,  fever,  loss  of  appetite,  night  sweats, 
lymphadenopathy  and  infection.  Some  patients  have 
enlarged lymph nodes in the neck or groin showed sign 
of  splenomegaly,  anemia,  thrombocytopenia  or 
infection  (Leonard,  1998).  Immunophenotyping  is 
useful  in  distinguishing  B-from  T-cell  disorders  and 
from  a  variety  of  the  related  lymphoproliferative 
disorders such as hairy cell leukemia, prolymphocytic 
leukemia,  lymphoplasmacytoid  lymphomas  and  the 
leukemic phase of follicular non-Hodgkin’s lymphoma 
(Catovsky et al., 1984). 
  CLL  has  no  standard  staging  system.  The  Rai’s 
staging  system  (Table  3)  and  the  Binet  classification 
(Table 4) are different from the staging used to evaluate 
other nonleukemic cancers. These systems are based on 
cytology. One commonly used system known as Rai’s 
staging system (Rai et al., 1975). 
 
Acute  Promyelocytic  Leukemia  (APL):  Acute 
Promyelocytic Leukemia (APL) is a subtype of acute 
Myelogenous  Leukemia  (AML)  characterized  by 
proliferating abnormal promyelocytes (Kingsley et al., 
1987). It is classified as the M3 variant of AML in the 
internationally  accepted  French-American-British 
(FAB) Classification. APL cells are heavily granulated 
promyelocytes,  often  with  bundles  of  Auer  rods 
(Mughal  and  Goldman,  2003).  It  also  occurs  in  a 
variant or microgranular form (Golomb et al., 1987).  
  APL  represents  approximately  10-15%  of  acute 
myeloid  leukemias  in  adults.  The  median  age  is 
approximately 40 years, which is considerably younger 
than the other subtypes of AML (Tallman et al., 2002). 
Most  patients  with  this  disorder  present  with  a 
hemorrhagic  diathesis  usually  associated  with 
Disseminated  Intravascular  Coagulation  (DIC) 
(Kingsley et al., 1987). Bleeding is usually in the form 
of  petechiae,  which  correlate  the  degree  of 
thrombocytopenia or ecchymoses which generally are 
caused by DIC commonly seen in patients with APL 
(Tallman et al., 1997).  
  The human promyelocytic leukemia cells line (HL-
60) is the derivation of the myeloid cell line HL-60 
from  the  leukemic  blood  cell  population  of  a  36-
years  old  female  with  Acute  Promyelocytic 
Leukemia (APL) (Gallagher et al., 1979). The HL-60 
cell  line  proliferates  continuously  in  suspension 
culture  with  a  doubling  time  of  about  36-48  h 
(Collins et al., 1977).  
  The  cultured  HL-60  cells  have  certain  cytologic 
properties  that  have  been  associated  with  leukemic 
promyelocytes.  These  include  nuclear/cytoplasmic 
asynchrony, nuclear bleb formation and heavy azurophilic 
granulation. The cultured HL-60 cells lack other features 
that  have  been  described  for  promyelocytes  from  some 
cases  of  acute  promyelocytic  leukemia,  including 
morphologically  abnormal  granules  with  Auer  rod  and 
extensive  intracytoplasmic  fibril  formation  and 
deformation  and  dilatation  of  the  cisternae  of  the 
endoplasmic reticulum (Valdivieso et al., 1975).  
  These  promyelocytes  can  be  induced  to 
differentiate  into  granulocytes,  macrophages  or 
monocytes,  eosinophils  and  basophils  by  various 
chemical  inducer  and  culture  condition  (Matsuhisa 
and  Mori,  1995). Thus,  HL-60  cell  line provides  a 
unique  in  vitro  model  system  for  studying  the 
cellular  and  molecular  events  where  aqueous 
environment, suspended and round cells are needed 
(Ratanachoo et al., 2002). 
 
Leukemia therapy: Cytotoxic drug and their future: 
Drug used in the treatment of leukemia represent a wide 
range of classes with different mode of actions. Until 
the  late  1980s,  induction  therapy  for  patients  with 
Acute Promyelocytic Leukemia (APL) was similar to 
all other patients with Acute Myeloid Leukemia (AML) 
and included an anthracycline and cytarabine. However, 
the  leukemic  cells  from  patients  with  APL  are 
peculiarly sensitive to anthracyclines, perhaps because 
of significantly lower P-glycoprotein (P-gp) expression 
and  other  resistance  markers  in  APL  cells  compared 
with other subtypes of AML (Lowenberg et al., 2003). 
Both  daunorubicin  and  idarubicin  as  single  agents 
induce Complete Remission (CR) in 60-80% of patients 
(Witz et al., 1998). Am. J. Immunol., 7 (4): 54-61, 2011 
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  Current  evidence  appears  compelling  that  an 
anthracyline  (daunorubicin  or  idarubicin)  should  be 
included  in  induction  in  contrast  to  cytarabine  which 
probably  can  be  omitted  (Tallman  et  al.,  2002). 
Anthracycline  (doxorubicin, daunorubicin,  idarubicin, 
mitroxantrone) is a class of antibiotic drugs is regularly 
used  to  treat  a  variety  of  cancers.  Despite  their 
widespread  use,  their  mechanism  of  action  remains 
unclear.  Three  postulates  exist.  Anthracyclines 
intercalate  between  DNA  base  pairs  leading  to 
unwinding of the superhelix and interfering with DNA 
and RNA synthesis, they undergo metabolism to form 
free radicals and they inhibit topoisomerase II, resulting 
in DNA strand breakage (Mazzotta et al., 2001).  
  Note that mitroxantrine is an anthracenedione, an 
anthracycline-like  compound  with  reduced  ability  to 
form free radicals. Daunorubicin, which has a narrower 
spectrum of utility than doxorubicin, is mainly used in 
the treatment of acute leukemia. Doxorubicin is used to 
treat  a  number  of  solid  tumours  as  well  as  multiple 
myeloma,  Hodgkin’s  disease,  non-Hodgkin’s 
lymphoma and acute lymphocytic leukemia. Idarubicin 
is  used  in  the  treatment  of  acute  myeloid  leukemia 
(Mazzotta et al., 2001).  
  Anthracyclines  are  metabolized  in  the  liver  and 
excreted in the bile. Dose reduction for patients with 
decreased liver function is recommended, especially if 
hyperbilirubinemia  is  present.  Myelosuppression, 
mucositis and cardiac toxicity are common toxicities 
of  these  drugs.  Irreversible  cardiac  toxicity  is 
thought to occur via drug induced oxidative damage 
by  free  radicals.  The  use  of  lower  doses  and 
dexrazoxane (an iron chelator that blocks generation 
of free radicals) had been shown to prevent cardiac 
toxicity  without  loss  of  antitumour  activity. 
Mitroxantrine causes less cardiotoxicity, nausea and 
vomiting (Mazzotta et al., 2001).  
  A recently study has shown that patients with APL 
fare  just  as  well  without  cytarabine  as  part  of  their 
induction or consolidation treatment (Sanz et al., 1999). 
The introduction of All-Trans Retinoic Acid (ATRA) 
has  prompted  several  study  groups  to  exploit  this 
peculiar  sensitivity  to  anthracyclines  by  omitting 
cytarabine during induction. Nevertheless, the evidence 
appears  compelling  that  cytarabine  can  be  omitted 
during induction when an anthracycline is given with 
ATRA.  The  European  APL  Group  is  currently 
conducting a trial in which patients presenting with a 
White Blood Cell (WBC) count of 10,000  L
-1 or fewer 
are prospectively and randomly assigned to ATRA and 
daunorubicin  or  to  ATRA  plus  daunorubicin  and 
cytarabine (Tallman et al., 2002).  
  Most patients  with acute promyelocytic leukemia 
can be put in complete clinical remission by daily oral 
administration of all-trans retinoic acid (tretinoin). Side 
effects  include  headache,  dry  skin,  xerostomia  and 
itching.  Leukocytosis  and  transient  elevation  of  liver 
enzymes are often observed. Up to 40% of patients with 
APL being treated with ATRA develop a syndrome of 
fever,  respiratory  distress,  pulmonary  infiltrates  and 
effusions.  The  syndrome  is  usually  reversible  with 
steroid  treatment.  Because  the  response  to  ATRA 
usually lasts only 3-5 months, with resistance rapidly 
developing,  ATRA  is  stopped  soon  after  complete 
remission is achieved and conventional chemotherapy 
regimens are administered (Warrell et al., 1993). 
  More  recently,  there  are  many  types  of  natural 
products  particularly  from  plants  derived  substances 
possess  inhibitory  and  suppressive  effect  against 
leukemic  cancer  cells.  Extracts  from  plants  such  as 
Elephantopus  scaber,  Vernonia  amygdalina,  Zingiber 
zerumbet,  Morinda  elliptica,  Micromelum  minutum, 
Triticum  aestivum  and  Goniothalamus  macrophyllus 
have  showed  their  cytotoxicity  and  potential  to  kill 
various type of leukemic cancer cells (Ho et al., 2009; 
Yeap et al., 2010b; 2012; Alitheen et al., 2010; 2011; 
Al-Qubaisi et al., 2011; Saeed and Elias, 2010; Tan et 
al.,  2009;  Faujan  et  al.,  2010).  Compounds  isolated 
from  these  plants  were  found  to  contribute  to  the 
cytotoxicity  against  leukemic  cancer  cell.  Process  of 
discovering potential natural  compounds antileukemia 
activity  can  be  shorten  using  Quantitative  Structure 
Activity  Relationship  (QSAR)  study  (Pugazhenthi  and 
Rajagopalan, 2009; Saeed and Elias, 2010). Other than 
direct cytotoxicity, concept of inhibiting the growth of 
leukemic cancer cell via modulating the immune system 
by  the  immunomodulator  agents  also  receiving 
inadequate  attention.  Plant  extract  such  as 
Rhaphidophora  korthalsii  (Yeap  et  al.,  2011)  and 
compounds  isolated  from  ginger  including  Zerumbone 
and Curcumin have found to inhibit leukemic cell lines 
via  stimulation  of  anticancer  cytokines  (Yeap  et  al., 
2010a; Gao et al., 2004).  
 
CONCLUSION 
 
  Research direction to discover novel chemotherapy 
agents for leukemia should focus on identifying natural 
compounds  which  carry  both  cytotoxic  and 
immunomodulatory  effects  while  possess  low  or  no 
toxicity against normal cell.  Am. J. Immunol., 7 (4): 54-61, 2011 
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